| Study Name | Description | Trial Category Sort descending | Trial SubCategory |
|---|---|---|---|
| EA3132 | This study is comparing radiation therapy with and without Cisplatin. You must have surgically resected squamous cell carcinoma of the head and neck stage 3 or 4. | Cancer | Head and Neck |
| EA2176 | The purpose of this study is to see if adding immunotherpy to chemo is more effective than chemo alone. You must be diagnosed with metastatic anal cancer. | Cancer | Metastic Anal |
| EAA173 | The purpose of this study is determine if dararumumab enhances the effectiveness of revlimid in patients with smoldering myeloma. You must be diagnosed with asymptomatic high risk smoldering multiple myeloma. | Cancer | Smoldering Myeloma |
| S1922 | The purpose of this study is to determine the effectiveness of Ramucirumab and Paclitaxel vs Folfiri chemo. You must be diagnosed with metastatic or unresectable small bowel cancer. | Cancer | Small Bowel |
| A032002 | The purpose of this study is to compare immunotherapy alone vs immunotherapy in combination with radiation for patients with metastatic Urothelial cancer. | Cancer | Metastatic Urothelial |
| S1608 | This study is for patients who have failed to achieve a complete remission or have relapsed within 2 years after completing treatment. You must have been diagnosed with follicular lymphoma grade 1, 2, or 3. | Cancer | Follicular Lymphoma |
| A221805 | This study is looking at using Duloxetine to prevent Oxaliplatin induced peripheral neuropathy. You must be diagnosed with stage 2 or 3 colorectal cancer scheduled to receive chemo with oxaliplatin. | Cancer | Colorectal |
| EAA181 | The purpose of this study is to determine what consolidation regimen is most effective. Patients cannot get stem cell transplant until first relapse or later. You must have newly diagnosed multiple myeloma (MM). | Cancer | Multiple Myeloma |
| S2001 | The purpose of this study is to determine the effectiveness of Olaparib + Prembrolizumab vs Olaparib alone. You must be diagnosed with metastatic pancreatic cancer with a BRCA1 or BRCA2 mutation. | Cancer | Pancreatic |
| A032103 | The purpose of this study is to use central DNA testing to monitor recurrance in patients with urothelial cancer. You must have had a radical cysectomy and lymph node dissection with no evidence of residual cancer. | Cancer | Urothelial |
| TAPUR | The purpose of this study is find targeted treatment for patients with advanced cancer that has a actionable genomic variant revealed by genomic testing. Tissue from your cancer must be sent for genomic screening. You must have an advanced solid tumor, mulitple myeloma or B cell non-Hodgkin lymphona for which standard treatment options are no longer available. | Cancer | All tumor types |
| EA5163 | The purpose of this study is to evaluate overall survival using immunotherapy alone or in combination with chemotherapy in advanced non-squamous Non-Small Cell Lung Cancer (NSCLC). You must be diagnosed with stage 4 Non-Small Cell Lung Cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| S1925 | The purpose of this study is to compare early intervention with Venetoclax and Obinutuzumab vs delayed therapy in newly diagnosed asymptomatic high0risk patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). You must have been diagnosed with CLL or SLL within the last 12 months. | Cancer | Hematology |
| EAY191 ComboMATCH | The purpose of this study is to find targeted therapy for specific gene mutations in metastatic or advanced cancer. You must have progressed on standard of care treatment or have a cancer which has no standard of care treatment. If select mutations are found you may be eligible for a sub-study. | Cancer | Genomics |
| S2107 | The purpose of this study is to see if adding immunotherpy to chemo is more effective than chemo alone. You must be diagnosed with metastatic colorectal cancer. | Cancer | Metastatic Colorectal |
| S2101 | This study is for patients with Stage III or IV, unresectable, recurrent, or metastatic melanoma. This study uses Nivolumab and Cabozantinib to treat patients. | Cancer | Melanoma |
| Agendia FLEX | The purpose of this study is to create a large population based database to identify new gene associations in breast cancer. You must be diagnosed with stage 1, 2 or 3 breast cancer. A report is created that looks at the risk of your cancer spreading over the next 10 years. | Cancer | Breast |
| S1706 | This study is looking at using Olaparib after a masectomy at the same time as radiation vs getting radiation alone to determine if adding the medication provides better results. | Cancer | Breast |
| EAY191-A6 ComboMATCH | The purpose of this study is to see if adding Binimetinib in combination with FOLFOX is more effective treatment. You must be diagnosed with biliary tract cancer with a MAPK pathway gene mutation. | Cancer | Biliary |
| S2200 | The purpose of this study is to compare treatment using cabozantinib with or without atezolizmab. You must be diagnosed with metastatic papillary renal cell cancer. | Cancer | Metastatic Renal Cell |
| EAY191-N5 | This study is for patient's who have HER2+ gynecologic cancers or other solid tumors. Cannot have breast cancer. You must have recurrent disease or progressed on treatment. | Cancer | Her2+ Solid Tumors |
| A151216 (ALCHEMIST) | The purpose of this study is to send tissue for screening of mutations to find targeted therapy for your cancer. You must be diagnosed with stage 1B, stage 2 or stage 3A resectable or completely resected non-small cell lung cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| A022102 | The purpose of this study is to compare effectiveness of mFOLFIRINOX with or without nivolumab and mFOLFOX6 with or without nivolumab . You must have newly diagnosed metastatic HER2 negative gastroesophageal cancer. | Cancer | Esophageal |
| EAY191-E4 ComboMATCH | The purpose of this study is to determine the effectiveness of nilotinib and paclitaxel in patients with prior taxane treated solid tumors. You must have had at least one prior line of therapy in the metastatic setting. | Cancer | Solid Tumors |
| S2212 | The purpose of this study is to compare anthracycline-free, taxane-platinum chemo with pembrolizumab to taxane-platinum-anthracycline chemo with pembrolizumab. This study is for people diagnosed with triple negative breast cancer. | Cancer | Breast |
| EA6141 | The purpose of this study is to compare the effectiveness of Nivolumab, Ipilimumab and Sargramostim vs Nivolumab and Ipilmumab. You must be diagnosed with unresectable stage 3 or stage 4 melanoma. | Cancer | Melanoma |
| A022101 | The purpose of this study is to evaluate radiation, ablation and surgery. You must be diagnosed with metastatic colorectal cancer. The primary tumor must be able to surgically resected. | Cancer | Colorectal |
| EAY191-N2 ComboMATCH | This study is for people diagnosed with hormone receptor positive breast cancer that has spread. A NF1 gene mutation must exist. | Cancer | Metastatic Breast |
| S2302 | This study is comparing Ramucirumab + Pembrolizumab vs standard of care chemo for patients previously treated with immunotherapy. You must be diagnosed with stage 4 or recurrent Non-Small Cell Lung Cancer (NSCLC). | Cancer | Metastatic Non-Small Cell Lung |
| E4512 (sub study A151216) | The purpose of this study is to compare Crizotinib vs observation for patients with a ALK+ Fusion Protein to determine if Crizotinib use results in improved disease-free survival. You must be diagnosed with stage 1B, stage 2 or stage 3A resectable or completely resected non-small cell lung cancer (NSCLC). | Cancer | Non-Small Lung |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.